Patent ID: 7645772

Claim:
A method for treating a mammalian subject with a condition selected from the group consisting of insulin resistance syndrome, Type II Diabetes, Type I Diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis comprising administering to the subject an amount of the biologically active agent effective to treat the condition; wherein the agent is selected from the group consisting of: 4-(4-benzyloxy-3-chlorophenyl)-4-oxobutanoic acid; Methyl 4-(4-benzyloxy-2-methoxyphenyl)-4-oxobutanoate; Ethyl 4-(4-cyclohexylmethoxyphenyl)-4-oxobutanoate; 4-(3-chloro-4-cyclopropylmethoxyphenyl)-4-oxobutanoic acid; Ethyl 3-(4-benzyloxyphenyl)-3-oxopropanoate; Ethyl 3-(3-benzyloxyphenyl)-3-oxopropanoate; Ethyl 3-(2-benzyloxyphenyl)-3-oxopropanoate; Methyl 3-(3-(2,6-dichlorobenzyloxy)phenyl)-3-oxopropanoate; Ethyl 3-(4-(4-chlorobenzyloxy)phenyl)-3-oxopropanoate; Ethyl 3-(3-(4-methoxybenzyloxy)phenyl)-3-oxopropanoate; Ethyl 3-(2-(4-methoxybenzyloxy)phenyl)-3-oxopropanoate; Ethyl 3-(2-(2-methoxybenzyloxy)phenyl)-3-oxopropanoate; Ethyl 3-(2-(3-methoxybenzyloxy)phenyl)-3-oxopropanoate; Ethyl 3-(4-benzyloxy-3-chlorophenyl)-3-oxopropanoate; Ethyl 3-(4-benzyloxy-3-methoxyphenyl)-3-oxopropanoate; Ethyl 3-(3-benzyloxy-4-methoxyphenyl)-3-oxopropanoate; and pharmaceutically acceptable salts thereof.